Company intelligence / Profile preview
OWC Pharmaceutical Research Corp.
- Ownership
- Private
- Employees
- ~50
- Development stage
- Other
Overview
OWC has completed two Phase I clinical trials demonstrating safety/tolerability of its lead cannabis-based products—a sublingual/oral tablet and a topical cream. No efficacy data or later-stage results are publicly available as of March 2025.
- Therapeutic areas
- OncologyPsychiatryDermatologyNeurology
- Modalities
- Cannabis-based therapeutics (including THC and CBD formulations)Topical creamsOrally disintegrating tablets
- Industry
- Biotech
Drug pipeline
1 assetBeyond the preview
Go deeper on OWC Pharmaceutical Research Corp..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OWC Pharmaceutical Research Corp..